Ashkan Pirmani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ashkan Pirmani has a total of 115 co-authors. Here are the top co-authors by number of shared publications:
- Liesbet M. Peeters
Biomedical Research Institute (BIOMED), University MS Center, Hasselt University, Diepenbeek, Belgium
9 shared publications Yves Moreau
ESAT, STADIUS, KU Leuven, Leuven, Belgium
5 shared publications- Yves Moreau
Department of Electrical Engineering, KU Leuven, Leuven
5 shared publications - Edward De Brouwer
ESAT-STADIUS KU Leuven
4 shared publications - Lotte Geys
University MS Centre (UMSC), Boemerangstraat 2, 3900, Pelt, Belgium
3 shared publications Rumen Ivanov
3 shared publications
Latest Publications
- Open Access
- 21 May 2026
- Published by IOS Press
- Vol. 336, 1093-1097
Good for All, Not Good Enough for One: Reuse Dilemma in Federated Learning
Federated learning (FL) promises privacy-aware collaboration in healthcare, but real-world adoption remains limited by infrastructural and organizational hurdles. In this paper, we reflect on our experience developing and later bypassing our own general-purpose FL framework, in favor of a task-specific pipeline. This case exposed five core barriers to reuse, ranging from workflow misalignment to governance constraints, that often go unaddressed in technical design. Rather than prescribing one approach over another, we argue for a shift toward modular, interoperable tools that can better accommodate the diversity of research contexts. Our findings highlight the need for realistic infrastructure thinking: one that acknowledges both the promise and the limits of reuse in practice.
- 21 May 2026
- Published by IOS Press
- Vol. 336, 1093-1097
Open AccessGood for All, Not Good Enough for One: Reuse Dilemma in Federated Learning
Federated learning (FL) promises privacy-aware collaboration in healthcare, but real-world adoption remains limited by infrastructural and organizational hurdles. In this paper, we reflect on our experience developing and later bypassing our own general-purpose FL framework, in favor of a task-specific pipeline. This case exposed five core barriers to reuse, ranging from workflow misalignment to governance constraints, that often go unaddressed in technical design. Rather than prescribing one approach over another, we argue for a shift toward modular, interoperable tools that can better accommodate the diversity of research contexts. Our findings highlight the need for realistic infrastructure thinking: one that acknowledges both the promise and the limits of reuse in practice.
- Open Access
- 21 May 2026
- Published by IOS Press
- Vol. 336, 230-231
Client Participation per Round in Federated Learning for Multiple Sclerosis with Real-World Data
We quantify how the per round client participation rate k affects performance and runtime in a federated learning study predicting two year confirmed disability progression in multiple sclerosis using routine clinical data. Using the original study’s data, preprocessing, model, and evaluation protocol, we vary k at 1.0, 0.6, and 0.4. Lower participation shortens wall time but can slightly reduce ROC – AUC and AUC – PR; k ≈ 0.6 preserved nearly all performance while cutting runtime by about one third.
- 21 May 2026
- Published by IOS Press
- Vol. 336, 230-231
Open AccessClient Participation per Round in Federated Learning for Multiple Sclerosis with Real-World Data
We quantify how the per round client participation rate k affects performance and runtime in a federated learning study predicting two year confirmed disability progression in multiple sclerosis using routine clinical data. Using the original study’s data, preprocessing, model, and evaluation protocol, we vary k at 1.0, 0.6, and 0.4. Lower participation shortens wall time but can slightly reduce ROC – AUC and AUC – PR; k ≈ 0.6 preserved nearly all performance while cutting runtime by about one third.
- 14 October 2025
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 324-331
Applying Federated Learning to Block-Term Tensor Regression for Decentralised Data Analysis of Biomedical Data
Block-Term Tensor Regression (BTTR) is a powerful method for modeling complex, high-dimensional data through multilinear relationships, making it well-suited for healthcare and neuroscience. However, its reliance on centralized datasets raises privacy concerns and limits collaboration. To address this, we propose Federated Block-Term Tensor Regression (FBTTR), an extension of BTTR for federated learning that enables decentralized model building while preserving privacy and regulatory compliance. We evaluate FBTTR in two case studies: finger movement decoding from Electrocorticography (ECoG) signals and disease risk prediction. On the BCI Competition IV dataset, FBTTR outperforms non-multilinear models and achieves higher accuracy than centralized BTTR (e.g., subject 3 thumb decoding: $0.76 \pm 0.05$ vs. $0.71 \pm 0.05$). On real-world clinical data, FBTTR surpasses both standard federated approaches and centralized BTTR (e.g., Fed-Heart-Disease Dataset AUC-ROC: $0.872 \pm 0.02$ vs. $0.812 \pm 0.003$; accuracy: $0.772 \pm 0.02$ vs. $0.753 \pm 0.007$). These results show that FBTTR is scalable, computationally efficient, and achieves predictive performance comparable to centralized models. Released as open-source software, it provides a practical and transparent framework for advancing federated analytics in healthcare and brain-computer interface applications.- 14 October 2025
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 324-331
Applying Federated Learning to Block-Term Tensor Regression for Decentralised Data Analysis of Biomedical Data
Block-Term Tensor Regression (BTTR) is a powerful method for modeling complex, high-dimensional data through multilinear relationships, making it well-suited for healthcare and neuroscience. However, its reliance on centralized datasets raises privacy concerns and limits collaboration. To address this, we propose Federated Block-Term Tensor Regression (FBTTR), an extension of BTTR for federated learning that enables decentralized model building while preserving privacy and regulatory compliance. We evaluate FBTTR in two case studies: finger movement decoding from Electrocorticography (ECoG) signals and disease risk prediction. On the BCI Competition IV dataset, FBTTR outperforms non-multilinear models and achieves higher accuracy than centralized BTTR (e.g., subject 3 thumb decoding: $0.76 \pm 0.05$ vs. $0.71 \pm 0.05$). On real-world clinical data, FBTTR surpasses both standard federated approaches and centralized BTTR (e.g., Fed-Heart-Disease Dataset AUC-ROC: $0.872 \pm 0.02$ vs. $0.812 \pm 0.003$; accuracy: $0.772 \pm 0.02$ vs. $0.753 \pm 0.007$). These results show that FBTTR is scalable, computationally efficient, and achieves predictive performance comparable to centralized models. Released as open-source software, it provides a practical and transparent framework for advancing federated analytics in healthcare and brain-computer interface applications.- Open Access
- 22 August 2024
- Published by IOS Press
- Vol. 316, 1582-1583
Unlocking the Power of Real-World Data: A Framework for Sustainable Healthcare
Real-world data (RWD) has the potential to revolutionize healthcare by offering valuable insights into patient outcomes and treatment efficacy. However, leveraging RWD effectively presents challenges, including its inherent limitations, diverse stakeholders, and insufficient data management pipelines. A proposed framework advocates three essential elements: adherence to FAIR principles (Findable, Accessible, Interoperable, and Reusable), stakeholder engagement and education, and highlighting the need for inclusive, pragmatic federated hybrid pipelines. By employing these strategies, healthcare organizations can overcome obstacles to RWD utilization and foster sustainable progress in patient care.
- 22 August 2024
- Published by IOS Press
- Vol. 316, 1582-1583
Open AccessUnlocking the Power of Real-World Data: A Framework for Sustainable Healthcare
Real-world data (RWD) has the potential to revolutionize healthcare by offering valuable insights into patient outcomes and treatment efficacy. However, leveraging RWD effectively presents challenges, including its inherent limitations, diverse stakeholders, and insufficient data management pipelines. A proposed framework advocates three essential elements: adherence to FAIR principles (Findable, Accessible, Interoperable, and Reusable), stakeholder engagement and education, and highlighting the need for inclusive, pragmatic federated hybrid pipelines. By employing these strategies, healthcare organizations can overcome obstacles to RWD utilization and foster sustainable progress in patient care.
- Open Access
- 17 July 2024
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 8 (1) , e55496
Accessible Ecosystem for Clinical Research (Federated Learning for Everyone): Development and Usability Study
Background: The integrity and reliability of clinical research outcomes rely heavily on access to vast amounts of data. However, the fragmented distribution of these data across multiple institutions, along with ethical and regulatory barriers, presents significant challenges to accessing relevant data. While federated learning offers a promising solution to leverage insights from fragmented data sets, its adoption faces hurdles due to implementation complexities, scalability issues, and inclusivity challenges. Objective: This paper introduces Federated Learning for Everyone (FL4E), an accessible framework facilitating multistakeholder collaboration in clinical research. It focuses on simplifying federated learning through an innovative ecosystem-based approach. Methods: The “degree of federation” is a fundamental concept of FL4E, allowing for flexible integration of federated and centralized learning models. This feature provides a customizable solution by enabling users to choose the level of data decentralization based on specific health care settings or project needs, making federated learning more adaptable and efficient. By using an ecosystem-based collaborative learning strategy, FL4E encourages a comprehensive platform for managing real-world data, enhancing collaboration and knowledge sharing among its stakeholders. Results: Evaluating FL4E’s effectiveness using real-world health care data sets has highlighted its ecosystem-oriented and inclusive design. By applying hybrid models to 2 distinct analytical tasks—classification and survival analysis—within real-world settings, we have effectively measured the “degree of federation” across various contexts. These evaluations show that FL4E’s hybrid models not only match the performance of fully federated models but also avoid the substantial overhead usually linked with these models. Achieving this balance greatly enhances collaborative initiatives and broadens the scope of analytical possibilities within the ecosystem. Conclusions: FL4E represents a significant step forward in collaborative clinical research by merging the benefits of centralized and federated learning. Its modular ecosystem-based design and the “degree of federation” feature make it an inclusive, customizable framework suitable for a wide array of clinical research scenarios, promising to revolutionize the field through improved collaboration and data use. Detailed implementation and analyses are available on the associated GitHub repository.
- 17 July 2024
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 8 (1) , e55496
Open AccessAccessible Ecosystem for Clinical Research (Federated Learning for Everyone): Development and Usability Study
Background: The integrity and reliability of clinical research outcomes rely heavily on access to vast amounts of data. However, the fragmented distribution of these data across multiple institutions, along with ethical and regulatory barriers, presents significant challenges to accessing relevant data. While federated learning offers a promising solution to leverage insights from fragmented data sets, its adoption faces hurdles due to implementation complexities, scalability issues, and inclusivity challenges. Objective: This paper introduces Federated Learning for Everyone (FL4E), an accessible framework facilitating multistakeholder collaboration in clinical research. It focuses on simplifying federated learning through an innovative ecosystem-based approach. Methods: The “degree of federation” is a fundamental concept of FL4E, allowing for flexible integration of federated and centralized learning models. This feature provides a customizable solution by enabling users to choose the level of data decentralization based on specific health care settings or project needs, making federated learning more adaptable and efficient. By using an ecosystem-based collaborative learning strategy, FL4E encourages a comprehensive platform for managing real-world data, enhancing collaboration and knowledge sharing among its stakeholders. Results: Evaluating FL4E’s effectiveness using real-world health care data sets has highlighted its ecosystem-oriented and inclusive design. By applying hybrid models to 2 distinct analytical tasks—classification and survival analysis—within real-world settings, we have effectively measured the “degree of federation” across various contexts. These evaluations show that FL4E’s hybrid models not only match the performance of fully federated models but also avoid the substantial overhead usually linked with these models. Achieving this balance greatly enhances collaborative initiatives and broadens the scope of analytical possibilities within the ecosystem. Conclusions: FL4E represents a significant step forward in collaborative clinical research by merging the benefits of centralized and federated learning. Its modular ecosystem-based design and the “degree of federation” feature make it an inclusive, customizable framework suitable for a wide array of clinical research scenarios, promising to revolutionize the field through improved collaboration and data use. Detailed implementation and analyses are available on the associated GitHub repository.
- Open Access
- 15 December 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Accessible Ecosystem for Clinical Research (Federated Learning for Everyone): Development and Usability Study (Preprint)
BACKGROUND The integrity and reliability of clinical research outcomes rely heavily on access to vast amounts of data. However, the fragmented distribution of these data across multiple institutions, along with ethical and regulatory barriers, presents significant challenges to accessing relevant data. While federated learning offers a promising solution to leverage insights from fragmented data sets, its adoption faces hurdles due to implementation complexities, scalability issues, and inclusivity challenges. OBJECTIVE This paper introduces Federated Learning for Everyone (FL4E), an accessible framework facilitating multistakeholder collaboration in clinical research. It focuses on simplifying federated learning through an innovative ecosystem-based approach. METHODS The “degree of federation” is a fundamental concept of FL4E, allowing for flexible integration of federated and centralized learning models. This feature provides a customizable solution by enabling users to choose the level of data decentralization based on specific health care settings or project needs, making federated learning more adaptable and efficient. By using an ecosystem-based collaborative learning strategy, FL4E encourages a comprehensive platform for managing real-world data, enhancing collaboration and knowledge sharing among its stakeholders. RESULTS Evaluating FL4E’s effectiveness using real-world health care data sets has highlighted its ecosystem-oriented and inclusive design. By applying hybrid models to 2 distinct analytical tasks—classification and survival analysis—within real-world settings, we have effectively measured the “degree of federation” across various contexts. These evaluations show that FL4E’s hybrid models not only match the performance of fully federated models but also avoid the substantial overhead usually linked with these models. Achieving this balance greatly enhances collaborative initiatives and broadens the scope of analytical possibilities within the ecosystem. CONCLUSIONS FL4E represents a significant step forward in collaborative clinical research by merging the benefits of centralized and federated learning. Its modular ecosystem-based design and the “degree of federation” feature make it an inclusive, customizable framework suitable for a wide array of clinical research scenarios, promising to revolutionize the field through improved collaboration and data use. Detailed implementation and analyses are available on the associated GitHub repository.
- 15 December 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessAccessible Ecosystem for Clinical Research (Federated Learning for Everyone): Development and Usability Study (Preprint)
BACKGROUND The integrity and reliability of clinical research outcomes rely heavily on access to vast amounts of data. However, the fragmented distribution of these data across multiple institutions, along with ethical and regulatory barriers, presents significant challenges to accessing relevant data. While federated learning offers a promising solution to leverage insights from fragmented data sets, its adoption faces hurdles due to implementation complexities, scalability issues, and inclusivity challenges. OBJECTIVE This paper introduces Federated Learning for Everyone (FL4E), an accessible framework facilitating multistakeholder collaboration in clinical research. It focuses on simplifying federated learning through an innovative ecosystem-based approach. METHODS The “degree of federation” is a fundamental concept of FL4E, allowing for flexible integration of federated and centralized learning models. This feature provides a customizable solution by enabling users to choose the level of data decentralization based on specific health care settings or project needs, making federated learning more adaptable and efficient. By using an ecosystem-based collaborative learning strategy, FL4E encourages a comprehensive platform for managing real-world data, enhancing collaboration and knowledge sharing among its stakeholders. RESULTS Evaluating FL4E’s effectiveness using real-world health care data sets has highlighted its ecosystem-oriented and inclusive design. By applying hybrid models to 2 distinct analytical tasks—classification and survival analysis—within real-world settings, we have effectively measured the “degree of federation” across various contexts. These evaluations show that FL4E’s hybrid models not only match the performance of fully federated models but also avoid the substantial overhead usually linked with these models. Achieving this balance greatly enhances collaborative initiatives and broadens the scope of analytical possibilities within the ecosystem. CONCLUSIONS FL4E represents a significant step forward in collaborative clinical research by merging the benefits of centralized and federated learning. Its modular ecosystem-based design and the “degree of federation” feature make it an inclusive, customizable framework suitable for a wide array of clinical research scenarios, promising to revolutionize the field through improved collaboration and data use. Detailed implementation and analyses are available on the associated GitHub repository.
- Open Access
- 9 November 2023
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 11 (1) , e48030
The Journey of Data Within a Global Data Sharing Initiative: A Federated 3-Layer Data Analysis Pipeline to Scale Up Multiple Sclerosis Research
Background: Investigating low-prevalence diseases such as multiple sclerosis is challenging because of the rather small number of individuals affected by this disease and the scattering of real-world data across numerous data sources. These obstacles impair data integration, standardization, and analysis, which negatively impact the generation of significant meaningful clinical evidence. Objective: This study aims to present a comprehensive, research question–agnostic, multistakeholder-driven end-to-end data analysis pipeline that accommodates 3 prevalent data-sharing streams: individual data sharing, core data set sharing, and federated model sharing. Methods: A demand-driven methodology is employed for standardization, followed by 3 streams of data acquisition, a data quality enhancement process, a data integration procedure, and a concluding analysis stage to fulfill real-world data-sharing requirements. This pipeline’s effectiveness was demonstrated through its successful implementation in the COVID-19 and multiple sclerosis global data sharing initiative. Results: The global data sharing initiative yielded multiple scientific publications and provided extensive worldwide guidance for the community with multiple sclerosis. The pipeline facilitated gathering pertinent data from various sources, accommodating distinct sharing streams and assimilating them into a unified data set for subsequent statistical analysis or secure data examination. This pipeline contributed to the assembly of the largest data set of people with multiple sclerosis infected with COVID-19. Conclusions: The proposed data analysis pipeline exemplifies the potential of global stakeholder collaboration and underlines the significance of evidence-based decision-making. It serves as a paradigm for how data sharing initiatives can propel advancements in health care, emphasizing its adaptability and capacity to address diverse research inquiries.
- 9 November 2023
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 11 (1) , e48030
Open AccessThe Journey of Data Within a Global Data Sharing Initiative: A Federated 3-Layer Data Analysis Pipeline to Scale Up Multiple Sclerosis Research
Background: Investigating low-prevalence diseases such as multiple sclerosis is challenging because of the rather small number of individuals affected by this disease and the scattering of real-world data across numerous data sources. These obstacles impair data integration, standardization, and analysis, which negatively impact the generation of significant meaningful clinical evidence. Objective: This study aims to present a comprehensive, research question–agnostic, multistakeholder-driven end-to-end data analysis pipeline that accommodates 3 prevalent data-sharing streams: individual data sharing, core data set sharing, and federated model sharing. Methods: A demand-driven methodology is employed for standardization, followed by 3 streams of data acquisition, a data quality enhancement process, a data integration procedure, and a concluding analysis stage to fulfill real-world data-sharing requirements. This pipeline’s effectiveness was demonstrated through its successful implementation in the COVID-19 and multiple sclerosis global data sharing initiative. Results: The global data sharing initiative yielded multiple scientific publications and provided extensive worldwide guidance for the community with multiple sclerosis. The pipeline facilitated gathering pertinent data from various sources, accommodating distinct sharing streams and assimilating them into a unified data set for subsequent statistical analysis or secure data examination. This pipeline contributed to the assembly of the largest data set of people with multiple sclerosis infected with COVID-19. Conclusions: The proposed data analysis pipeline exemplifies the potential of global stakeholder collaboration and underlines the significance of evidence-based decision-making. It serves as a paradigm for how data sharing initiatives can propel advancements in health care, emphasizing its adaptability and capacity to address diverse research inquiries.
- Open Access
- 20 April 2023
- Published by JMIR Publications Inc. in JMIR Preprints
The Journey of Data Within a Global Data Sharing Initiative: A Federated 3-Layer Data Analysis Pipeline to Scale Up Multiple Sclerosis Research (Preprint)
BACKGROUND Investigating low-prevalence diseases such as multiple sclerosis is challenging because of the rather small number of individuals affected by this disease and the scattering of real-world data across numerous data sources. These obstacles impair data integration, standardization, and analysis, which negatively impact the generation of significant meaningful clinical evidence. OBJECTIVE This study aims to present a comprehensive, research question–agnostic, multistakeholder-driven end-to-end data analysis pipeline that accommodates 3 prevalent data-sharing streams: individual data sharing, core data set sharing, and federated model sharing. METHODS A demand-driven methodology is employed for standardization, followed by 3 streams of data acquisition, a data quality enhancement process, a data integration procedure, and a concluding analysis stage to fulfill real-world data-sharing requirements. This pipeline’s effectiveness was demonstrated through its successful implementation in the COVID-19 and multiple sclerosis global data sharing initiative. RESULTS The global data sharing initiative yielded multiple scientific publications and provided extensive worldwide guidance for the community with multiple sclerosis. The pipeline facilitated gathering pertinent data from various sources, accommodating distinct sharing streams and assimilating them into a unified data set for subsequent statistical analysis or secure data examination. This pipeline contributed to the assembly of the largest data set of people with multiple sclerosis infected with COVID-19. CONCLUSIONS The proposed data analysis pipeline exemplifies the potential of global stakeholder collaboration and underlines the significance of evidence-based decision-making. It serves as a paradigm for how data sharing initiatives can propel advancements in health care, emphasizing its adaptability and capacity to address diverse research inquiries.
- 20 April 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessThe Journey of Data Within a Global Data Sharing Initiative: A Federated 3-Layer Data Analysis Pipeline to Scale Up Multiple Sclerosis Research (Preprint)
BACKGROUND Investigating low-prevalence diseases such as multiple sclerosis is challenging because of the rather small number of individuals affected by this disease and the scattering of real-world data across numerous data sources. These obstacles impair data integration, standardization, and analysis, which negatively impact the generation of significant meaningful clinical evidence. OBJECTIVE This study aims to present a comprehensive, research question–agnostic, multistakeholder-driven end-to-end data analysis pipeline that accommodates 3 prevalent data-sharing streams: individual data sharing, core data set sharing, and federated model sharing. METHODS A demand-driven methodology is employed for standardization, followed by 3 streams of data acquisition, a data quality enhancement process, a data integration procedure, and a concluding analysis stage to fulfill real-world data-sharing requirements. This pipeline’s effectiveness was demonstrated through its successful implementation in the COVID-19 and multiple sclerosis global data sharing initiative. RESULTS The global data sharing initiative yielded multiple scientific publications and provided extensive worldwide guidance for the community with multiple sclerosis. The pipeline facilitated gathering pertinent data from various sources, accommodating distinct sharing streams and assimilating them into a unified data set for subsequent statistical analysis or secure data examination. This pipeline contributed to the assembly of the largest data set of people with multiple sclerosis infected with COVID-19. CONCLUSIONS The proposed data analysis pipeline exemplifies the potential of global stakeholder collaboration and underlines the significance of evidence-based decision-making. It serves as a paradigm for how data sharing initiatives can propel advancements in health care, emphasizing its adaptability and capacity to address diverse research inquiries.
- Top Cited PapersOpen Access
- 9 November 2021
- Published by Wolters Kluwer Health in Neurology
- Vol. 97 (19) , e1870-e1885
Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis
Background and Objectives People with multiple sclerosis (MS) are a vulnerable group for severe coronavirus disease 2019 (COVID-19), particularly those taking immunosuppressive disease-modifying therapies (DMTs). We examined the characteristics of COVID-19 severity in an international sample of people with MS. Methods Data from 12 data sources in 28 countries were aggregated (sources could include patients from 1–12 countries). Demographic (age, sex), clinical (MS phenotype, disability), and DMT (untreated, alemtuzumab, cladribine, dimethyl fumarate, glatiramer acetate, interferon, natalizumab, ocrelizumab, rituximab, siponimod, other DMTs) covariates were queried, along with COVID-19 severity outcomes, hospitalization, intensive care unit (ICU) admission, need for artificial ventilation, and death. Characteristics of outcomes were assessed in patients with suspected/confirmed COVID-19 using multilevel mixed-effects logistic regression adjusted for age, sex, MS phenotype, and Expanded Disability Status Scale (EDSS) score. Results Six hundred fifty-seven (28.1%) with suspected and 1,683 (61.9%) with confirmed COVID-19 were analyzed. Among suspected plus confirmed and confirmed-only COVID-19, 20.9% and 26.9% were hospitalized, 5.4% and 7.2% were admitted to ICU, 4.1% and 5.4% required artificial ventilation, and 3.2% and 3.9% died. Older age, progressive MS phenotype, and higher disability were associated with worse COVID-19 outcomes. Compared to dimethyl fumarate, ocrelizumab and rituximab were associated with hospitalization (adjusted odds ratio [aOR] 1.56, 95% confidence interval [CI] 1.01–2.41; aOR 2.43, 95% CI 1.48–4.02) and ICU admission (aOR 2.30, 95% CI 0.98–5.39; aOR 3.93, 95% CI 1.56–9.89), although only rituximab was associated with higher risk of artificial ventilation (aOR 4.00, 95% CI 1.54–10.39). Compared to pooled other DMTs, ocrelizumab and rituximab were associated with hospitalization (aOR 1.75, 95% CI 1.29–2.38; aOR 2.76, 95% CI 1.87–4.07) and ICU admission (aOR 2.55, 95% CI 1.49–4.36; aOR 4.32, 95% CI 2.27–8.23), but only rituximab was associated with artificial ventilation (aOR 6.15, 95% CI 3.09–12.27). Compared to natalizumab, ocrelizumab and rituximab were associated with hospitalization (aOR 1.86, 95% CI 1.13–3.07; aOR 2.88, 95% CI 1.68–4.92) and ICU admission (aOR 2.13, 95% CI 0.85–5.35; aOR 3.23, 95% CI 1.17–8.91), but only rituximab was associated with ventilation (aOR 5.52, 95% CI 1.71–17.84). Associations persisted on restriction to confirmed COVID-19 cases. No associations were observed between DMTs and death. Stratification by age, MS phenotype, and EDSS score found no indications that DMT associations with COVID-19 severity reflected differential DMT allocation by underlying COVID-19 severity. Discussion Using the largest cohort of people with MS and COVID-19 available, we demonstrated consistent associations of rituximab with increased risk of hospitalization, ICU admission, and need for artificial ventilation and of ocrelizumab with hospitalization and ICU admission. Despite the cross-sectional design of the study, the internal and external consistency of these results with prior studies suggests that rituximab/ocrelizumab use may be a risk factor for more severe COVID-19.
- 9 November 2021
- Published by Wolters Kluwer Health in Neurology
- Vol. 97 (19) , e1870-e1885
Top Cited PapersOpen AccessAssociations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis
Background and Objectives People with multiple sclerosis (MS) are a vulnerable group for severe coronavirus disease 2019 (COVID-19), particularly those taking immunosuppressive disease-modifying therapies (DMTs). We examined the characteristics of COVID-19 severity in an international sample of people with MS. Methods Data from 12 data sources in 28 countries were aggregated (sources could include patients from 1–12 countries). Demographic (age, sex), clinical (MS phenotype, disability), and DMT (untreated, alemtuzumab, cladribine, dimethyl fumarate, glatiramer acetate, interferon, natalizumab, ocrelizumab, rituximab, siponimod, other DMTs) covariates were queried, along with COVID-19 severity outcomes, hospitalization, intensive care unit (ICU) admission, need for artificial ventilation, and death. Characteristics of outcomes were assessed in patients with suspected/confirmed COVID-19 using multilevel mixed-effects logistic regression adjusted for age, sex, MS phenotype, and Expanded Disability Status Scale (EDSS) score. Results Six hundred fifty-seven (28.1%) with suspected and 1,683 (61.9%) with confirmed COVID-19 were analyzed. Among suspected plus confirmed and confirmed-only COVID-19, 20.9% and 26.9% were hospitalized, 5.4% and 7.2% were admitted to ICU, 4.1% and 5.4% required artificial ventilation, and 3.2% and 3.9% died. Older age, progressive MS phenotype, and higher disability were associated with worse COVID-19 outcomes. Compared to dimethyl fumarate, ocrelizumab and rituximab were associated with hospitalization (adjusted odds ratio [aOR] 1.56, 95% confidence interval [CI] 1.01–2.41; aOR 2.43, 95% CI 1.48–4.02) and ICU admission (aOR 2.30, 95% CI 0.98–5.39; aOR 3.93, 95% CI 1.56–9.89), although only rituximab was associated with higher risk of artificial ventilation (aOR 4.00, 95% CI 1.54–10.39). Compared to pooled other DMTs, ocrelizumab and rituximab were associated with hospitalization (aOR 1.75, 95% CI 1.29–2.38; aOR 2.76, 95% CI 1.87–4.07) and ICU admission (aOR 2.55, 95% CI 1.49–4.36; aOR 4.32, 95% CI 2.27–8.23), but only rituximab was associated with artificial ventilation (aOR 6.15, 95% CI 3.09–12.27). Compared to natalizumab, ocrelizumab and rituximab were associated with hospitalization (aOR 1.86, 95% CI 1.13–3.07; aOR 2.88, 95% CI 1.68–4.92) and ICU admission (aOR 2.13, 95% CI 0.85–5.35; aOR 3.23, 95% CI 1.17–8.91), but only rituximab was associated with ventilation (aOR 5.52, 95% CI 1.71–17.84). Associations persisted on restriction to confirmed COVID-19 cases. No associations were observed between DMTs and death. Stratification by age, MS phenotype, and EDSS score found no indications that DMT associations with COVID-19 severity reflected differential DMT allocation by underlying COVID-19 severity. Discussion Using the largest cohort of people with MS and COVID-19 available, we demonstrated consistent associations of rituximab with increased risk of hospitalization, ICU admission, and need for artificial ventilation and of ocrelizumab with hospitalization and ICU admission. Despite the cross-sectional design of the study, the internal and external consistency of these results with prior studies suggests that rituximab/ocrelizumab use may be a risk factor for more severe COVID-19.
- Open Access
- 1 November 2021
- Published by Consortium of Multiple Sclerosis Centers in International Journal of MS Care
- Vol. 23 (6) , 261-268
The Multiple Sclerosis Data Alliance Catalogue
Background: One of the major objectives of the Multiple Sclerosis Data Alliance (MSDA) is to enable better discovery of multiple sclerosis (MS) real-world data (RWD).Methods: We implemented the MSDA Catalogue, which is available worldwide. The current version of the MSDA Catalogue collects descriptive information on governance, purpose, inclusion criteria, procedures for data quality control, and how and which data are collected, including the use of e-health technologies and data on collection of COVID-19 variables. The current cataloguing procedure is performed in several manual steps, securing an effective catalogue.Results: Herein we summarize the status of the MSDA Catalogue as of January 6, 2021. To date, 38 data sources across five continents are included in the MSDA Catalogue. These data sources differ in purpose, maturity, and variables collected, but this landscaping effort shows that there is substantial alignment on some domains. The MSDA Catalogue shows that personal data and basic disease data are the most collected categories of variables, whereas data on fatigue measurements and cognition scales are the least collected in MS registries/cohorts.Conclusions: The Web-based MSDA Catalogue provides strategic overview and allows authorized end users to browse metadata profiles of data cohorts and data sources. There are many existing and arising RWD sources in MS. Detailed cataloguing of MS RWD is a first and useful step toward reducing the time needed to discover MS RWD sets and promoting collaboration.
- 1 November 2021
- Published by Consortium of Multiple Sclerosis Centers in International Journal of MS Care
- Vol. 23 (6) , 261-268
Open AccessThe Multiple Sclerosis Data Alliance Catalogue
Background: One of the major objectives of the Multiple Sclerosis Data Alliance (MSDA) is to enable better discovery of multiple sclerosis (MS) real-world data (RWD).Methods: We implemented the MSDA Catalogue, which is available worldwide. The current version of the MSDA Catalogue collects descriptive information on governance, purpose, inclusion criteria, procedures for data quality control, and how and which data are collected, including the use of e-health technologies and data on collection of COVID-19 variables. The current cataloguing procedure is performed in several manual steps, securing an effective catalogue.Results: Herein we summarize the status of the MSDA Catalogue as of January 6, 2021. To date, 38 data sources across five continents are included in the MSDA Catalogue. These data sources differ in purpose, maturity, and variables collected, but this landscaping effort shows that there is substantial alignment on some domains. The MSDA Catalogue shows that personal data and basic disease data are the most collected categories of variables, whereas data on fatigue measurements and cognition scales are the least collected in MS registries/cohorts.Conclusions: The Web-based MSDA Catalogue provides strategic overview and allows authorized end users to browse metadata profiles of data cohorts and data sources. There are many existing and arising RWD sources in MS. Detailed cataloguing of MS RWD is a first and useful step toward reducing the time needed to discover MS RWD sets and promoting collaboration.